Comparative Pharmacology
Head-to-head clinical analysis: ISOVUE 250 versus ISOVUE 370.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOVUE 250 versus ISOVUE 370.
ISOVUE-250 vs ISOVUE-370
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iopamidol is a nonionic, water-soluble iodinated radiographic contrast agent that attenuates X-rays, thereby providing contrast enhancement in imaging studies. Its mechanism of action is physical rather than pharmacological, as it does not have inherent biological activity.
Iodinated contrast agent that attenuates X-rays, providing radiographic contrast by increasing the density of vascular structures and tissues.
Intravenous administration of 50-150 mL (12-37 g iodine) for CT imaging; intra-arterial administration of 10-80 mL (2.5-20 g iodine) for angiography; dose depends on procedure and patient weight.
Intravenous injection of 50-200 mL of Isovue-370 (iopamidol 76% solution, 370 mg I/mL) for adults, administered as a bolus or infusion depending on imaging protocol. Typical dose for CT: 100-150 mL total volume.
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours (normal renal function); clinically, half-life prolonged in renal impairment
Terminal elimination half-life is approximately 1.5-2 hours in patients with normal renal function (creatinine clearance >60 mL/min); prolonged to up to 30 hours in severe renal impairment.
Primarily renal: 90-95% unchanged in urine within 24 hours; biliary/fecal: <5%
Primarily renal (glomerular filtration) with >95% of administered dose excreted unchanged in urine within 24 hours. Less than 1% excreted in feces.
Category C
Category C
Contrast Media
Contrast Media